UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 36

Sortiert nach

Therapeutic antibodies for infectious diseases

Bulletin of the World Health Organization, 2017-03, Vol.95 (3), p.235-237

2017

Link zum Volltext

Verfügbarkeit prüfen

Global production capacity of seasonal and pandemic influenza vaccines in 2019

Vaccine, 2021-01, Vol.39 (3), p.512-520

2021

Link zum Volltext

Verfügbarkeit prüfen

Biological factors that may impair transplacental transfer of RSV antibodies: Implications for maternal immunization policy and research priorities for low- and middle-income countries

Vaccine, 2022-07, Vol.40 (32), p.4361-4370

2022

Link zum Volltext

Verfügbarkeit prüfen

Changes in the global hospitalisation burden of respiratory syncytial virus in young children during the COVID-19 pandemic: a systematic analysis

The Lancet infectious diseases, 2024-04, Vol.24 (4), p.361-374

2024

Link zum Volltext

Verfügbarkeit prüfen

H7N9 live attenuated influenza vaccine in healthy adults: a randomised, double-blind, placebo-controlled, phase 1 trial

The Lancet infectious diseases, 2016-03, Vol.16 (3), p.303-310

2016

Link zum Volltext

Verfügbarkeit prüfen

Rationale for vaccination with trivalent or quadrivalent live attenuated influenza vaccines: Protective vaccine efficacy in the ferret model

PloS one, 2018-12, Vol.13 (12), p.e0208028

2018

Link zum Volltext

Verfügbarkeit prüfen

Safety and immunogenicity of a seasonal trivalent inactivated split influenza vaccine: a phase I randomized clinical trial in healthy Serbian adults

Human vaccines & immunotherapeutics, 2018-03, Vol.14 (3), p.579-586

2018

Link zum Volltext

Verfügbarkeit prüfen

Technology transfer programme for influenza vaccines – Lessons from the past to inform the future

Vaccine, 2022-08, Vol.40 (33), p.4673-4675

2022

Link zum Volltext

Verfügbarkeit prüfen

The 2015 global production capacity of seasonal and pandemic influenza vaccine

Vaccine, 2016-10, Vol.34 (45), p.5410-5413

2016

Link zum Volltext

Verfügbarkeit prüfen

Safety and immunogenicity of a seasonal trivalent inactivated split influenza vaccine: a double blind, phase III randomized clinical trial in healthy Serbian adults

Therapeutic advances in vaccines and immunotherapy, 2020, Vol.8, p.251513552092533

2020

Link zum Volltext

Verfügbarkeit prüfen

Passive immunization for influenza through antibody therapies, a review of the pipeline, challenges and potential applications

Vaccine, 2016-10, Vol.34 (45), p.5442-5448

2016

Link zum Volltext

Verfügbarkeit prüfen

Two Live Attenuated Vaccines against Recent Low⁻and Highly Pathogenic H7N9 Influenza Viruses Are Safe and Immunogenic in Ferrets

Vaccines (Basel), 2018-11, Vol.6 (4), p.74

2018

Link zum Volltext

Verfügbarkeit prüfen

Recent advances in the development of monoclonal antibodies for rabies post exposure prophylaxis: A review of the current status of the clinical development pipeline

Vaccine, 2019-10, Vol.37, p.A132-A139

2019

Link zum Volltext

Verfügbarkeit prüfen

The full value of immunisation against respiratory syncytial virus for infants younger than 1 year: effects beyond prevention of acute respiratory illness

The Lancet infectious diseases, 2024-05, Vol.24 (5), p.e318-e327

2024

Link zum Volltext

Verfügbarkeit prüfen

The role of vaccines in reducing antimicrobial resistance: A review of potential impact of vaccines on AMR and insights across 16 vaccines and pathogens

Vaccine, 2024-07, Vol.42 (19), p.S1-S8

2024

Link zum Volltext

Verfügbarkeit prüfen

Report of the WHO technical consultation on the evaluation of respiratory syncytial virus prevention cost effectiveness in low- and middle-income countries, April 7–8, 2022

Vaccine, 2023-11, Vol.41 (48), p.7047-7059

2023

Link zum Volltext

Verfügbarkeit prüfen

Value profile for respiratory syncytial virus vaccines and monoclonal antibodies

Vaccine, 2023-11, Vol.41 Suppl 2, p.S7-S40

2023

Link zum Volltext

Verfügbarkeit prüfen

Stakeholders’ perceptions of 10 years of the Global Action Plan for Influenza Vaccines (GAP) – Results from a survey

Vaccine, 2016-10, Vol.34 (45), p.5393-5399

2016

Link zum Volltext

Verfügbarkeit prüfen

Stakeholders’ perceptions of 10years of the Global Action Plan for Influenza Vaccines (GAP) – Results from a survey

Vaccine, 2016-10, Vol.34 (45), p.5393-5399

2016

Link zum Volltext

Verfügbarkeit prüfen

Cross-Protective Efficacy of Monovalent Live Influenza B Vaccines against Genetically Different Lineages of B/Victoria and B/Yamagata in Ferrets

BioMed research international, 2018-01, Vol.2018, p.9695628-11

2018

Link zum Volltext

Verfügbarkeit prüfen

Leveraging mRNA Platform Technology to Accelerate Development of Vaccines for Some Emerging and Neglected Tropical Diseases Through Local Vaccine Production

Frontiers in tropical diseases, 2022-07, Vol.3

2022

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 36

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(33)
Mit Volltextzugriff
(35)

Publikationsform

Sprache

Englisch
(36)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

Science & Technology
(28)
Life Sciences & Biomedicine
(25)
Humans
(20)
Vaccines
(18)
Immunology
(13)
Medicine, Research & Experimental
(13)
Research & Experimental Medicine
(13)
Viruses
(13)
Influenza
(12)
Immunization
(11)
Pandemics
(11)
Public Health
(9)
Female
(8)
Influenza, Human - Prevention & Control
(8)
Animals
(7)
Clinical Trials
(7)
Infant
(6)
Infections
(6)
Infectious Diseases
(6)
Monoclonal Antibodies
(6)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Therapeutic antibodies for infectious diseases

Global production capacity of seasonal and pandemic influenza vaccines in 2019

Biological factors that may impair transplacental transfer of RSV antibodies: Implications for maternal immunization policy and research priorities for low- and middle-income countries

Changes in the global hospitalisation burden of respiratory syncytial virus in young children during the COVID-19 pandemic: a systematic analysis

H7N9 live attenuated influenza vaccine in healthy adults: a randomised, double-blind, placebo-controlled, phase 1 trial

Safety and immunogenicity of a live attenuated influenza H5 candidate vaccine strain A/17/turkey/Turkey/05/133 H5N2 and its priming effects for potential pre-pandemic use: a randomised, double-blind, placebo-controlled trial

Rationale for vaccination with trivalent or quadrivalent live attenuated influenza vaccines: Protective vaccine efficacy in the ferret model

Safety and immunogenicity of a seasonal trivalent inactivated split influenza vaccine: a phase I randomized clinical trial in healthy Serbian adults

Technology transfer programme for influenza vaccines – Lessons from the past to inform the future

The 2015 global production capacity of seasonal and pandemic influenza vaccine

Safety and immunogenicity of a seasonal trivalent inactivated split influenza vaccine: a double blind, phase III randomized clinical trial in healthy Serbian adults

Passive immunization for influenza through antibody therapies, a review of the pipeline, challenges and potential applications

A Phase 1 Randomized Placebo-Controlled Study to Assess the Safety, Immunogenicity and Genetic Stability of a New Potential Pandemic H7N9 Live Attenuated Influenza Vaccine in Healthy Adults

Two Live Attenuated Vaccines against Recent Low⁻and Highly Pathogenic H7N9 Influenza Viruses Are Safe and Immunogenic in Ferrets

Recent advances in the development of monoclonal antibodies for rabies post exposure prophylaxis: A review of the current status of the clinical development pipeline

The full value of immunisation against respiratory syncytial virus for infants younger than 1 year: effects beyond prevention of acute respiratory illness

The role of vaccines in reducing antimicrobial resistance: A review of potential impact of vaccines on AMR and insights across 16 vaccines and pathogens

WHO preferred product characteristics for monoclonal antibodies for passive immunization against respiratory syncytial virus (RSV) disease in infants – Key considerations for global use

Report of the WHO technical consultation on the evaluation of respiratory syncytial virus prevention cost effectiveness in low- and middle-income countries, April 7–8, 2022

Value profile for respiratory syncytial virus vaccines and monoclonal antibodies

Stakeholders’ perceptions of 10 years of the Global Action Plan for Influenza Vaccines (GAP) – Results from a survey

Stakeholders’ perceptions of 10years of the Global Action Plan for Influenza Vaccines (GAP) – Results from a survey

Dose-sparing effect of two adjuvant formulations with a pandemic influenza A/H7N9 vaccine: A randomized, double-blind, placebo-controlled, phase 1 clinical trial

Cross-Protective Efficacy of Monovalent Live Influenza B Vaccines against Genetically Different Lineages of B/Victoria and B/Yamagata in Ferrets

Leveraging mRNA Platform Technology to Accelerate Development of Vaccines for Some Emerging and Neglected Tropical Diseases Through Local Vaccine Production

Suchergebnisse filtern